Cassava Sciences, Inc. (FRA:PX91)
Germany · Delayed Price · Currency is EUR 2.871
-0.114 (-3.82%)
At close: Nov 28, 2025
Cassava Sciences Company Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.
The company was incorporated in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.
| Country | United States |
| Founded | 1998 |
| Industry | Pharmaceutical Preparations |
| Employees | 30 |
| CEO | Richard Barry |
Contact Details
Address: 6801 N. Capital of Texas Highway Austin, Delaware 78731 United States | |
| Phone | 512 501 2444 |
| Website | cassavasciences.com |
Stock Details
| Ticker Symbol | PX91 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Barry | Chief Executive Officer |
| Eric Schoen | Chief Financial Officer |
| R. Cook | Chief Operating Officer |